Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.57 USD
Change Today +0.24 / 1.95%
Volume 770.7K
ADXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Key Developments

Advaxis, Inc. Presents Preliminary Data from a Phase 1/2 Trial of ADXS-HPV

Advaxis, Inc. presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 â “ 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea. The data were highlighted in an oral presentation by Kimberly Perez, M.D., Assistant Professor of Medicine at the Alpert Medical School, Brown University, during the recent International Anal Neoplasia Society (IANS) Scientific Meeting 2015, in Atlanta, Georgia.

Advaxis, Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 09:05 AM

Advaxis, Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 09:05 AM. Venue: The University Club, 1 W 54th St, New York, NY 10019, United States.

Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM

Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Daniel J. O'Connor, Chief Executive Officer, President and Director.

Advaxis, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM

Advaxis, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

Advaxis, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015

Advaxis, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Presentation Date & Speakers: Feb-23-2015, Robert G. Petit, Chief Scientific Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $12.57 USD +0.24

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $8.84 USD -0.08
Eurocine Vaccines AB kr2.80 SEK -0.02
Genocea Biosciences Inc $11.58 USD -0.24
GenVec Inc $3.02 USD +0.06
Inovio Pharmaceuticals Inc $8.09 USD -0.10
View Industry Companies
 

Industry Analysis

ADXS

Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 265.7x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 304.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.